Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03087058 |
|
Recruitment Status :
Suspended
(Recruitment temporarily halted to reassess pediatric development plan)
First Posted : March 22, 2017
Last Update Posted : March 24, 2022
|
Sponsor:
Vifor Pharma, Inc.
Information provided by (Responsible Party):
Vifor Pharma ( Vifor Pharma, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the change in serum (blood) potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - < 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too much potassium in the blood). Another purpose of the study is to evaluate the safety and tolerability of patiromer in children 2 - < 18 years of age with CKD and hyperkalemia.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hyperkalemia | Drug: Patiromer | Phase 2 |
Up to 54 subjects, 2 - < 18 years of age with CKD (estimated glomerular filtration rate [eGFR] < 90 mL/min/1.73 m2 ) and hyperkalemia (two potassium measurements of 5.1 to < 6.5 mEq/L performed on separate days) will be enrolled in this open-label, multiple-dose, Phase 2 study.
The study will include two treatment phases: Pharmacodynamic (PD; drug effect on potassium) / Dose Finding Phase consisting of the initial 14-day dose finding period followed by an up to 5.5-month Long-Term Treatment Phase for a total study participation duration for individual subjects of up to 6.5 months (includes a 2 week follow up period).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 54 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age With Chronic Kidney Disease and Hyperkalemia |
| Actual Study Start Date : | May 1, 2017 |
| Estimated Primary Completion Date : | September 2022 |
| Estimated Study Completion Date : | September 2022 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Patiromer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1
Patiromer for age 12 - < 18 years
|
Drug: Patiromer
4.2 g/day, 8.4 g/day and 16.8 g/day
Other Names:
|
|
Experimental: Cohort 2
Patiromer for age 6 - < 12 years
|
Drug: Patiromer
2 g/day, 4 g/day and 8 g/day
Other Names:
|
|
Experimental: Cohort 3
Patiromer for age 2 - < 6 years
|
Drug: Patiromer
1 g/day, 2 g/day and 4 g/day
Other Names:
|
Primary Outcome Measures :
- Change in serum potassium (K+) levels from Baseline to Day 14 [ Time Frame: Baseline and Day 14 ]Changes in serum potassium levels will be summarized by starting dose and age group using descriptive statistics. Descriptive statistics include mean, standard deviation, and 95% confidence intervals.
Secondary Outcome Measures :
- Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L at Day 14 (Initial PD / Dose Finding Phase) [ Time Frame: Day 14 ]Proportions and associated exact 95% confidence interval will be presented.
- Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L by visit at any time through Month 6 (Long-Term Treatment Phase) [ Time Frame: Up to Month 6 ]Proportions and associated 95% confidence interval will be presented.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written assent (when applicable) and written informed consent by a legally authorized representative provided prior to participation in the study
- Age 2 - <18 years old
- CKD defined by the estimated glomerular filtration rate (eGFR) <90 mL/min/1.73m2, including renal transplant subjects, based on local creatinine measurement at screening
- Two potassium measurements of 5.1 to < 6.5 mEq/L performed on separate days
- In the opinion of the study doctor, is expected to require treatment for hyperkalemia for at least 6 month
- If taking any renin-angiotensin-aldosterone system inhibitors (RAASi) beta blockers or diuretic medications, must be on a stable dose for at least 28 days prior to Screening
- Negative pregnancy test in females of child-bearing potential
Exclusion Criteria:
- Pseudohyperkalemia due to hemolysis or to abnormally high numbers of platelets (>500,000/mm3), leukocytes (>70,000/mm3), or erythrocytes (hematocrit >55%) at Screening based on results obtained locally
- Evidence of potassium-related electrocardiogram (ECG) changes at Screening
- Any of the following kidney conditions: maintenance hemodialysis or peritoneal dialysis, renal artery stenosis, and acute kidney injury or a history of acute renal insufficiency in the past 3 months
- Severe disorder of stomach or intestines including surgery that could affect gastrointestinal transit of the drug
- Increased liver enzymes (ALT, AST > 3 times upper limit of normal) at Screening
- Active cancer, currently on cancer treatment or history of cancer in the past 2 years (except for non-melanoma skin cancer)
- Heart or liver transplant, or anticipated need for transplant during the study treatment period including a scheduled kidney transplant recipient. (Note: patients currently on a kidney transplant wait list are not excluded unless there is an identified donor).
- Alcohol abuse or substance use disorder within 1 year of Screening
- Subjects currently being treated with or having taken any one of the following medications (includes resins) in the 7 days prior to Screening: sodium or calcium polystyrene sulfonate, drospirenone
- Use of certain medications that can affect blood potassium levels if doses have not been stable for at least 14 days prior to Screening or if doses are anticipated to change during the 14-day PD / Dose Finding Phase
- Use of investigational product within 30 days of screening or within 5 half-lives, whichever is longer
- Known hypersensitivity to patiromer or its components
- In the opinion of the Investigator, any medical condition, uncontrolled systemic disease, or serious intercurrent illness that would significantly decrease study compliance or jeopardize the safety of the subject or potentially affect the quality of the data
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03087058
Locations
Show 30 study locations
Sponsors and Collaborators
Vifor Pharma, Inc.
Investigators
| Study Director: | Udo-Michael Göhring | Vifor Pharma, Inc. |
| Responsible Party: | Vifor Pharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT03087058 |
| Other Study ID Numbers: |
RLY5016-206p 2016-002785-31 ( EudraCT Number ) |
| First Posted: | March 22, 2017 Key Record Dates |
| Last Update Posted: | March 24, 2022 |
| Last Verified: | March 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Vifor Pharma ( Vifor Pharma, Inc. ):
|
Treatment of Hyperkalemia Hyperkalemia Potassium Chronic Kidney Disease |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency, Chronic Hyperkalemia Urologic Diseases |
Renal Insufficiency Water-Electrolyte Imbalance Metabolic Diseases |